Literature DB >> 20838937

Idiopathic pulmonary fibrosis-an epidemiological and pathological review.

Andrea T Borchers1, Christopher Chang, Carl L Keen, M Eric Gershwin.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease (ILD) affecting the pulmonary interstitium. Other forms of interstitial lung disease exist, and in some cases, an environmental etiology can be delineated. The diagnosis of IPF is typically established by high-resolution CT scan. IPF tends to have a worse prognosis than other forms of ILD. Familial cases of IPF also exist, suggesting a genetic predisposition; telomerase mutations have been observed to occur in familial IPF, which may also explain the increase in IPF with advancing age. Alveolar epithelial cells are believed to be the primary target of environmental agents that have been putatively associated with IPF. These agents may include toxins, viruses, or the autoantibodies found in collagen vascular diseases. The mechanism of disease is still unclear in IPF, but aberrations in fibroblast differentiation, activation, and proliferation may play a role. Epithelial-mesenchymal transition may also be an important factor in the pathogenesis, as it may lead to accumulation of fibroblasts in the lung and a disruption of normal tissue structure. Abnormalities in other components of the immune system, including T cells, B cells, and dendritic cells, as well as the development of ectopic lymphoid tissue, have also been observed to occur in IPF and may play a role in the stimulation of fibrosis that is a hallmark of the disease. It is becoming increasingly clear that the pathogenesis of IPF is indeed a complex and convoluted process that involves numerous cell types and humoral factors.

Entities:  

Mesh:

Year:  2011        PMID: 20838937     DOI: 10.1007/s12016-010-8211-5

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  148 in total

1.  Synergy between CD40 ligation and IL-4 on fibroblast proliferation involves IL-4 receptor signaling.

Authors:  Sergei P Atamas; Irina G Luzina; Heqiao Dai; Susan G Wilt; Barbara White
Journal:  J Immunol       Date:  2002-02-01       Impact factor: 5.422

2.  Incidence and prevalence of idiopathic pulmonary fibrosis.

Authors:  Ganesh Raghu; Derek Weycker; John Edelsberg; Williamson Z Bradford; Gerry Oster
Journal:  Am J Respir Crit Care Med       Date:  2006-06-29       Impact factor: 21.405

3.  Usual interstitial pneumonitis is a T-cell alveolitis.

Authors:  R L Kradin; M B Divertie; R B Colvin; J Ramirez; J Ryu; H A Carpenter; A K Bhan
Journal:  Clin Immunol Immunopathol       Date:  1986-08

4.  Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis.

Authors:  Marco Chilosi; Venerino Poletti; Alberto Zamò; Maurizio Lestani; Licia Montagna; Paola Piccoli; Serena Pedron; Manuela Bertaso; Aldo Scarpa; Bruno Murer; Alessandra Cancellieri; Roberta Maestro; Gianpietro Semenzato; Claudio Doglioni
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

5.  Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK.

Authors:  J Gribbin; R B Hubbard; I Le Jeune; C J P Smith; J West; L J Tata
Journal:  Thorax       Date:  2006-07-14       Impact factor: 9.139

6.  Role of diabetes mellitus and gastro-oesophageal reflux in the aetiology of idiopathic pulmonary fibrosis.

Authors:  Jonathan Gribbin; Richard Hubbard; Chris Smith
Journal:  Respir Med       Date:  2008-12-06       Impact factor: 3.415

7.  Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis.

Authors:  R W Tobin; C E Pope; C A Pellegrini; M J Emond; J Sillery; G Raghu
Journal:  Am J Respir Crit Care Med       Date:  1998-12       Impact factor: 21.405

8.  Compartmentalized expression of c-FLIP in lung tissues of patients with idiopathic pulmonary fibrosis.

Authors:  Seung-Ick Cha; Steve D Groshong; Stephen K Frankel; Ben L Edelman; Gregory P Cosgrove; Jennifer L Terry-Powers; Linda K Remigio; Douglas Curran-Everett; Kevin K Brown; Carlyne D Cool; David W H Riches
Journal:  Am J Respir Cell Mol Biol       Date:  2009-04-16       Impact factor: 6.914

9.  A rearranged form of Epstein-Barr virus DNA is associated with idiopathic pulmonary fibrosis.

Authors:  Brian G Kelly; She S Lok; Philip S Hasleton; Jim J Egan; James P Stewart
Journal:  Am J Respir Crit Care Med       Date:  2002-08-15       Impact factor: 21.405

10.  Pathology of asbestosis- An update of the diagnostic criteria: Report of the asbestosis committee of the college of american pathologists and pulmonary pathology society.

Authors:  Victor L Roggli; Allen R Gibbs; Richard Attanoos; Andrew Churg; Helmut Popper; Philip Cagle; Bryan Corrin; Teri J Franks; Francoise Galateau-Salle; Jeff Galvin; Philip S Hasleton; Douglas W Henderson; Koichi Honma
Journal:  Arch Pathol Lab Med       Date:  2010-03       Impact factor: 5.534

View more
  25 in total

1.  Nickle(II) ions exacerbate bleomycin-induced pulmonary inflammation and fibrosis by activating the ROS/Akt signaling pathway.

Authors:  Lawei Yang; Ziying Lin; Yahong Wang; Chunyan Li; Wenya Xu; Qinglan Li; Weimin Yao; Zeqing Song; Gang Liu
Journal:  Environ Sci Pollut Res Int       Date:  2017-11-28       Impact factor: 4.223

2.  A novel genomic signature with translational significance for human idiopathic pulmonary fibrosis.

Authors:  Yasmina Bauer; John Tedrow; Simon de Bernard; Magdalena Birker-Robaczewska; Kevin F Gibson; Brenda Juan Guardela; Patrick Hess; Axel Klenk; Kathleen O Lindell; Sylvie Poirey; Bérengère Renault; Markus Rey; Edgar Weber; Oliver Nayler; Naftali Kaminski
Journal:  Am J Respir Cell Mol Biol       Date:  2015-02       Impact factor: 6.914

Review 3.  Peripheral blood biomarkers in idiopathic pulmonary fibrosis.

Authors:  Rekha Vij; Imre Noth
Journal:  Transl Res       Date:  2012-02-02       Impact factor: 7.012

Review 4.  B-lymphocyte lineage cells and the respiratory system.

Authors:  Atsushi Kato; Kathryn E Hulse; Bruce K Tan; Robert P Schleimer
Journal:  J Allergy Clin Immunol       Date:  2013-04       Impact factor: 10.793

5.  Upregulated has-miR-4516 as a potential biomarker for early diagnosis of dust-induced pulmonary fibrosis in patients with pneumoconiosis.

Authors:  Ruixue Huang; Ting Yu; Ying Li; Jianan Hu
Journal:  Toxicol Res (Camb)       Date:  2018-02-08       Impact factor: 3.524

6.  Negative impact of hyperglycaemia on mouse alveolar development.

Authors:  Mei-Yao He; Guang Wang; Sha-Sha Han; Ke Li; Ya Jin; Meng Liu; Zhen-Peng Si; Ju Wang; Guo-Sheng Liu; Xuesong Yang
Journal:  Cell Cycle       Date:  2017-12-21       Impact factor: 4.534

Review 7.  Therapeutic update in idiopathic pulmonary fibrosis.

Authors:  Andrew L Chan; Rokhsara Rafii; Samuel Louie; Timothy E Albertson
Journal:  Clin Rev Allergy Immunol       Date:  2013-02       Impact factor: 8.667

8.  Bleomycin delivery by osmotic minipump: similarity to human scleroderma interstitial lung disease.

Authors:  Rebecca Lee; Charles Reese; Michael Bonner; Elena Tourkina; Zoltan Hajdu; Ellen C Riemer; Richard M Silver; Richard P Visconti; Stanley Hoffman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-02-28       Impact factor: 5.464

9.  A review of current and novel therapies for idiopathic pulmonary fibrosis.

Authors:  Rokhsara Rafii; Maya M Juarez; Timothy E Albertson; Andrew L Chan
Journal:  J Thorac Dis       Date:  2013-02       Impact factor: 2.895

10.  Plasma B lymphocyte stimulator and B cell differentiation in idiopathic pulmonary fibrosis patients.

Authors:  Jianmin Xue; Daniel J Kass; Jessica Bon; Louis Vuga; Jiangning Tan; Eva Csizmadia; Leo Otterbein; Makoto Soejima; Marc C Levesque; Kevin F Gibson; Naftali Kaminski; Joseph M Pilewski; Michael Donahoe; Frank C Sciurba; Steven R Duncan
Journal:  J Immunol       Date:  2013-07-19       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.